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Abstract
Background: The decision of transarterial chemoembolization (TACE) initiation and/or repetition remains
challenging in patients with unresectable hepatocellular carcinoma (HCC). The aim was to develop a prognostic
scoring system to guide TACE initiation/repetition.
Methods: A total of 597 consecutive patients who underwent TACE as their initial treatment for unresectable HCC
were included. We derived a prediction model using independent risk factors for overall survival (OS), which was
externally validated in an independent cohort (n = 739).
Results: Independent risk factors of OS included Albumin-bilirubin (ALBI) grade, maximal tumor size, alpha-
fetoprotein, and tumor response to initial TACE, which were used to develop a scoring system (“ASAR”). C-index
values for OS were 0.733 (95% confidence interval [CI] = 0.570–0.871) in the derivation, 0.700 (95% CI = 0.445–0.905)
in the internal validation, and 0.680 (95% CI = 0.652–0.707) in the external validation, respectively. Patients with
ASAR< 4 showed significantly longer OS than patients with ASAR≥4 in all three datasets (all P < 0.001). Among
Child-Pugh class B patients, a modified model without TACE response, i.e., “ASA(R)”, discriminated OS with a c-index
of 0.788 (95% CI, 0.703–0.876) in the derivation, and 0.745 (95% CI, 0.646–0.862) in the internal validation, and 0.670
(95% CI, 0.605–0.725) in the external validation, respectively. Child-Pugh B patients with ASA(R) < 4 showed
significantly longer OS than patients with ASA(R) ≥ 4 in all three datasets (all P < 0.001).
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Conclusions: ASAR provides refined prognostication for repetition of TACE in patients with unresectable HCC. For
Child-Pugh class B patients, a modified model with baseline factors might guide TACE initiation.
Keywords: Hepatocellular carcinoma, Transarterial chemoembolization, Child-Pugh classification, Risk prediction
model
Background
Hepatocellular carcinoma (HCC) remains the fifth most
common malignancy and is the second most common
cause of cancer-related mortality worldwide [1]. Because
many patients are still diagnosed with unresectable dis-
eases, transarterial chemoembolization (TACE) is the
standard treatment for such patients in the absence of
macroscopic vascular invasion or extrahepatic spread,
which comprises mostly intermediate stage or Barcelona
Clinic Liver Cancer (BCLC) stage B [2, 3]. However, the
survival benefit of TACE is not universal even in pa-
tients with same tumor stage, mainly because of the het-
erogeneity of the tumor burden and/or the hepatic
functional reserve [4, 5].
Several strategies for patient selection in terms of initi-
ation or repetition of TACE have been suggested, mostly
combining tumor factors and hepatic functional reserve: for
example, hepatoma arterial-embolization prognostic (HAP)
score (Supplementary material), BCLC B sub-classification,
Assessment for Retreatment with TACE (ART) score, etc.
[5–8] However, some subsequent studies on these strat-
egies have reported mixed results [5, 9–11]. Given that the
decision of TACE as an initial treatment primarily depends
on hepatic functional reserve for patients with TACE-
treatable tumors, TACE is mostly reserved for those with
Child-Pugh class A or for highly selected Child-Pugh class
B patients without decompensation [2, 3]. For patients with
Child-Pugh class A undergoing repeated sessions of TACE,
it is important to predict TACE failure or refractoriness
early enough to shift toward systemic treatment at an ap-
propriate timing. However, for Child-Pugh class B patients,
proper patient selection for the initiation of TACE seems
relevant to prevent further deterioration of hepatic function
and the resulting worsening in patient survival. Thus, a dif-
ferentiated approach for patient selection based on hepatic
function is required for patients who are potential candi-
dates for TACE.
Hepatic functional reserve has traditionally been
assessed using the Child-Pugh system [12]. However, the
Child-Pugh system has several limitations such as inclu-
sion of subjective variables (ascites and encephalopathy
grade), absence of weighting for each variable, and
changeable cut-off [13]. In this regard, the albumin-
bilirubin (ALBI) grade (Supplementary material) was de-
veloped to assess hepatic function of HCC patients,
using only objective variables (combination of serum
albumin and bilirubin), and has shown to be useful in
stratifying HCC patients across different stages [14–16].
In addition to hepatic functional assessment, tumor bur-
den should also be included in the decision making of
initiation or repetition of TACE.
Thus, the present study aimed to develop and validate
a prognostic scoring system using a combination of hep-
atic function and tumor factors, and investigate the out-
comes according to the scores to shed light on patient
selection for the initiation or repetition of TACE based




In this multi-center cohort study, eligible HCC patients
were evaluated for eligibility from three large-volume
university hospitals in South Korea (i.e., Seoul National
University Hospital [SNUH], Ewha Womans University
Medical Center [EUMC], and Samsung Medical Center
[SMC]). We included consecutive patients meeting all
the following inclusion criteria: 1) the patients with
unresectable HCC of BCLC A or B; 2) the patients who
received conventional TACE as their initial treatment; 3)
the patients aged ≥18 years. The diagnosis of HCC was
based on histological examination or clinicoradiological
criteria according to international guidelines [2, 3].
Among a total of 763 consecutive HCC patients from
SNUH (between January 2012 and April 2014, n = 542)
and EUMC (between January 2011 and December 2015,
n = 221) who were considered eligible, 166 patients (n =
121 in SNUH and n = 45 in EUMC) were excluded be-
cause of the following reasons: poor performance state
(ECOG≥1, n = 39); Child-Pugh class B9 or C (n = 44),
current or previous features of decompensation (i.e., un-
controlled ascites, variceal hemorrhage, or hepatic en-
cephalopathy; n = 60), and follow-up loss (n = 23).
Among these patients, Thus, 597 patients were enrolled
for analysis, and were randomly assigned to either the
derivation (n = 419) or the internal validation set (n =
178) stratified by age and sex at a 7:3 ratio (Fig. 1). For
an independent cohort for external validation, 750 HCC
patients who met the abovementioned criteria were eval-
uated for eligibility from SMC (between January 2007
and December 2012). Of these, 11 patients were ex-
cluded because of history of decompensation or Child-
Nam et al. BMC Cancer          (2020) 20:504 Page 2 of 14
Pugh score of 9 or higher. Finally, 739 patients from
SMC were enrolled for external validation.
The present study was approved by the institutional
review boards of the three participating institutions and
was conducted following the ethical guidelines of the
World Medical Association Declaration of Helsinki. In-
formed patient consent was waived by the institutional
review board of each institution owing to the retrospect-
ive nature of the study.
TACE procedure and treatment schedule
TACE procedures were performed using the superselec-
tive method by experienced interventional radiologists
(over 10 years of experience) in study hospitals [17]. The
principles of TACE procedures were largely similar be-
tween three institutions in terms of superselectivity,
choice of chemotherapeutic agents and treatment sched-
ule as described elsewhere [18, 19]. Briefly, an arterial
catheter was inserted into the femoral artery using the
Seldinger technique and elective angiography of the ce-
liac axis was performed. Then the catheter was advanced
into the desired hepatic artery branch. Tumor-feeding
vessels were superselected whenever possible, and a sus-
pension containing 20–60 mg of doxorubicin hydro-
chloride (ADM, Dong-A Pharmacy, Seoul, Korea) and
2–20 mL of iodized oil (Lipiodol, Guerbet, Aulnay-sous-
Bois, France) with absorbable gelatin sponge particles
(Gelfoam, Upjohn, Kalamazoo, MI) was infused through
a catheter (5-Fr) or a microcatheter (2.8- or 3-Fr) placed
in the tumor-feeding arteries. The dosages of doxorubi-
cin and iodized oil and the use of gelatin sponge parti-
cles were determined for each patient based on tumor
burden, tumor characteristics, and hepatic functional re-
serve [20, 21]. Repeated TACE treatments were consid-
ered if residual or newly developed tumors were
detected on dynamic computed tomography (CT) or
magnetic resonance imaging (MRI) undertaken 4–6
weeks following each TACE session and were performed
on an “on-demand” basis depending on individual tumor
response and hepatic functional reserve.
Outcomes and assessments
The primary outcome was overall survival (OS), which
was measured from the date of HCC diagnosis to the
date of death from any cause. Survival data of the en-
rolled patients were obtained from the national statis-
tical data provided by the Korean Ministry of
Government Administration and Home Affairs. The data
cut-off date was November 30, 2017. The secondary out-
come assessed was tumor response. Tumor responses
were evaluated after every TACE session with the modi-
fied Response Evaluation Criteria in Solid Tumors cri-
teria [22]. The efficacy of the performed TACE was
determined by evaluating the pattern of iodized oil re-
tention in the target lesions as an indicator of tumor ne-
crosis [23]. Iodized oil retention was considered as
compact on imaging when the contrast medium was
well scattered throughout all viable target lesions;
Fig. 1 Consort diagram. A total of 763 HCC patients who received TACE as initial treatment for unresectable HCC were enrolled from two large-
volume university hospitals. Of these, 166 patients were excluded and 597 patients were enrolled for analysis. A total of 739 HCC patients from
independent university hospital were enrolled to validate the model externally
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otherwise, it was regarded as non-compact uptake [24].
Patients without residual viable tumor after TACE were
followed-up with dynamic CT or MRI every 8–12 weeks.
All scans were reviewed by two independent radiologists
with > 10 years of experience who were unaware of the
group assignment. In cases of discordance, an additional
third independent experienced radiologist reviewed the
images and a consensus was reached among the three.
Statistical analysis
Baseline characteristics were presented as mean ± stand-
ard deviation for normally distributed continuous vari-
ables and median with interquartile ranges (IQRs) for
continuous variables with a skewed distribution. Discrete
variables were summarized by the number of subjects
with percentages. To compare baseline characteristics
between groups, we used the Student’s t-test or Mann-
Whitney U test, as appropriate. Distribution of categor-
ical variables was compared using the chi-square and
Fisher’s exact test. OS was calculated as the time from
HCC diagnosis until death from any cause. Survival ana-
lysis was performed using the Kaplan-Meier analysis and
the log-rank test was used to compare between groups.
Tumor- and hepatic function-related prognostic factors
for OS were explored using the Cox proportional-
hazards regression analysis. Based on the results of the
univariate analyses, factors with a significant difference
(P < 0.05) were included in the multivariate model for
development of a prediction model. A prediction model
for OS was developed using relevant parameters identified
by forward stepwise selection. A model with the minimum
Akaike information criterion value was selected, which
rewarded the goodness-of-fit of the model. Basically, we
performed a proportional-hazards hypothesis for the se-
lected models. The proportional-hazards hypothesis was
checked via the Schoenfeld residuals method. The predict-
ive ability was evaluated by using concordance (c)-statis-
tics for discrimination function and Hosmer-Lemeshow
test for calibration function. These were performed after
excluding the variables sequentially to develop the sim-
plest model out of candidate models developed. When the
result of the Hosmer-Lemeshow test was satisfied (P >
0.05) and the c-statistics was 0.7 or more, the difference in
c-statistics between the models was compared and the
simplest model was selected if there was no statistically
significant difference. To obtain the optimism corrected
value of the c-statistics, we applied 100-times bootstraps.
In the final model, a relative score of each risk factor was
assigned based on the estimated coefficient value, and the
risk score for prediction of OS was calculated in each sub-
ject. Based on the results of the pairwise log-rank test, the
patients were divided into subgroups by the OS score and
survival curves were compared between the subgroups. In-
ternal and external validation of the developed prediction
model was conducted, and sensitivity analyses were per-
formed under various conditions (e.g., among patients
with Child-Pugh class A or B). A two-sided P < 0.05 was
considered statistically significant. All statistical analysis




Table 1 summarizes the baseline characteristics of the
overall included patients. The median age was 63 in
SNUH, 69 in EUMC, and 63 years in SMC. The propor-
tion of male was 79.1% in SNUH, 80.1% in EUMC, and
78.9% in SMC. The etiology of the underlying liver dis-
ease was mostly viral. The number tumors over 3 were
found in 72 (17.1%) patients of SNUH, 32 (18.2%) of
EUMC, and 120 (16.2%) of SMC. The maximal tumor
diameter over 5 cm was found in 113 (26.8%) of SNUH,
57 (32.4%) of EUMC, and 272 (36.8%) of SMC. The me-
dian alpha-fetoprotein (AFP) level ≥ 200 ng/mL was
found in 89 (21.1%) of SNUH, 49 (28.5%) of EUMC, and
194 (26.3%) of SMC. The patient with Child-Pugh class
B was 85 (20.2%) in SMUH, 33 (18.8%) in EUMC, and
101 (13.7%) in SMC. The HAP score D were found in
24 patients (5.7%) in SNUH, 23 (13.1%) in EUMC, and
50 (6.8%) in SMC, respectively. ALBI grades 3 were 17
patients (4.0%) in SNUH, 13 (7.4%) in EUMC, and 15
(2.0%) in SMC (Table 1). The time intervals between the
diagnosis of HCC and the initial TACE were 2.0 weeks
(1.8–3.0) in SNU cohort and 2.0 weeks (1.0–2.8) in
EUMC cohort (P = 0.115), suggesting that there was no
significant time delay between the diagnosis and the ini-
tial treatment in both cohorts.
There were no significant differences between the two
hospital cohorts (SNUH and EUMC) with respect to sex,
etiology, Child-Pugh class, tumor number, tumor size,
and AFP. However, the patients in the EUMC cohort
were significantly older (69 [59–78] vs. 63 [54–71] years)
and had higher ALBI grades (grade 2: 67.0% vs. 58.2%),
HAP scores (score D: 13.1% vs. 5.7%), and modified
HAP scores (score D: 5.1% vs. 1.2%) than those in the
SNUH cohort (Supplementary Table 1). Thus, instead of
using each hospital cohort as either the derivation or the
internal validation set, the two hospital cohorts were di-
vided into two groups in a proportion of 7:3, which were
stratified for age and sex to minimize the influence of
discrepancies between the two hospital cohorts. Follow-
ing the division into two sets, the discrepancies in base-
line characteristics largely diminished between the
derivation and internal validation sets, as shown in
Table 2. Baseline characteristics of patients from SMC
were also shown in Table 1. The patients of SMC were
analyzed as an external validation set.
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Table 1 Baseline characteristics of the entire cohort
Variables SNUH (n = 421) EUMC (n = 176) SMC (n = 739) P
Sex
Male 333 (79.1) 141 (80.1) 583 (78.9) 0.938
Female 88 (20.9) 35 (19.9) 156 (21.1)
Age (year) 63 (54–71) 69 (59–78) 63 (56–70) < 0.001
Etiology
HBV 265 (63.0) 121 (74.6) 517 (70.0) 0.005
HCV 56 (13.3) 26 (16.0) 97 (13.1)
alcohol 45 (10.7) 15 (9.4) 67 (9.0)
Cirrhosis
Yes 336 (79.8%) 134 (76.1%) 443 (60.0) < 0.001
Child-Pugh classa
A 336 (79.8) 143 (81.3) 638 (86.3) 0.010
B 85 (20.2) 33 (18.8) 101 (13.7)
BCLC stage
A 168 (39.9) 69 (39.2) 500 (67.7) < 0.001
B 253 (60.1) 107 (60.8) 239 (32.3)
ALBI grade
1 159 (37.8) 45 (25.6) 339 (45.9) < 0.001
2 245 (58.2) 118 (67.0) 385 (52.1)
3 17 (4.0) 13 (7.4) 15 (2.0)
HAP score
A 157 (37.3) 58 (33.0) 233 (31.5) 0.016
B 134 (31.8) 47 (26.7) 252 (34.1)
C 106 (25.2) 48 (27.3) 204 (27.6)
D 24 (5.7) 23 (13.1) 50 (6.8)
Modified HAP score
A 211 (50.1) 71 (40.4) 98 (13.3) < 0.001
B 150 (35.6) 67 (38.1) 259 (35.0)
C 55 (13.1) 29 (16.5) 235 (31.8)
D 5 (1.2) 9 (5.1) 147 (19.9)
Tumor number
≤3 349 (82.9) 143 (81.7) 619 (82.8) 0.715
> 3 72 (17.1) 32 (18.2) 120 (16.2)
Tumor size (cm)
< 3 179 (42.5) 68 (38.6) 304 (41.1) < 0.001
3–5 129 (30.6) 51 (29.0) 163 (22.1)
≥5 113 (26.8) 57 (32.4) 272 (36.8)
Hemoglobin (g/dL) 13.0 (11.8–14.3) 13.2 (11.3–14.5) 13.8 (12.7–14.8) < 0.001
WBC (×103/μL) 5.1 (3.9–6.3) 5.1 (3.9–6.3) 5.1 (4.0–6.6) 0.430
Platelet (× 103/μL) 120 (81–165) 132 (91–179) 129 (87–175) 0.406
Prothrombin time (INR) 1.1 (1.0–1.2) 1.1 (1.1–1.2) 1.1 (1.1–1.2) < 0.001
Creatinine (mg/dL) 0.8 (0.7–1.0) 0.9 (0.8–1.1) 0.9 (0.8–1.0) < 0.001
Sodium (mEq/L) 141 (139–142) 139 (137–141) 140 (138–142) < 0.001
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Identification of prognostic factors of OS after initial TACE
treatment
The Cox proportional hazards analyses were performed
in the derivation set. Univariate Cox analysis was per-
formed to select prognostic factors associated with OS,
and the following variables were significantly associated
with OS: Child-Pugh class B, AFP ≥200 ng/mL, ALBI
grade 2, tumor number ≥ 3, maximal tumor diameter ≥ 5
cm, initial TACE response, and HAP score D. Multivari-
ate analysis identified four independent predictors for
OS as follows: ALBI grade (adjusted hazard ratio [aHR],
2.299; 95% CI, 1.694–3.119; P < 0.001), maximal tumor
diameter (aHR, 1.704; 95% CI, 1.424–2.038; P < 0.001),
AFP (aHR, 1.583; 95% CI, 1.164–2.154; P = 0.003), and
initial TACE response (aHR, 1.915; 95% CI, 1.431–2.563;
P < 0.001) (Table 3).
Prediction model development for evaluating TACE
suitability
Through forward stepwise selection, a scoring system was
developed including the aforementioned four independent
predictors for OS (i.e., ALBI, tumor size, AFP, initial
TACE response; abbreviated as “ASAR”) as shown in
Table 4. Regression coefficients of the factors were 0.832
(ALBI grade), 0.533 (maximal tumor diameter), 0.460
(AFP), and 0.650 (initial TACE response). The weighted
scores (0, 1, and 2) for the ASAR scoring system were
assigned for the four covariates based on the regression
coefficients that were obtained from the final analysis and
the total scores ranged from 0 to 6. We confirmed the
simplest model according to the result of the Hosmer-
Lemeshow test and c-statistics between models with the
abovementioned statistical methodology. C-index for OS
was 0.733 (95% CI, 0.570–0.871) in the derivation set,
which was maintained at 0.733 (95% CI, 0.703–0.768) with
100-fold bootstrapping. In the internal validation, the c-
index was 0.700 (95% CI, 0.445–0.905). Goodness-of-fit
for the ASAR model was confirmed in both the derivation
and the internal validation sets (P = 0.360 and P = 0.926,
respectively, by Hosmer-Lemeshow χ2 test). In the exter-
nal validation set, c-index was maintained at 0.680 (95%
CI, 0.652–0.707).
Based on the pairwise log-rank test results, the cut-off
value was designated as 4, which presented the greatest
difference in the survival curves of the derivation set. In
the derivation set, patients with ASAR < 4 had signifi-
cantly longer OS than ASAR ≥4 (hazard ratio [HR],
0.233; 95% CI, 0.171–0.317; P < 0.001; Fig. 2a). In the in-
ternal validation set, patients with ASAR < 4 had signifi-
cantly longer OS than ASAR ≥4 (HR, 0.287; 95% CI,
0.176–0.468; P < 0.001; Fig. 2b). Thus, we designated
ASAR < 4 as the low-risk group and ASAR ≥4 as the
high-risk group. Among 178 patients of the internal val-
idation set, the proportion of patients who were not
amenable to further treatment after initial TACE was
higher in the high-risk group (4 out of 29, 13.8%) than
in the low-risk group (5 out of 149, 3.4%) (P = 0.019). Of
these nine patients, six patients died after first TACE
and three patients received best supportive care. We also
compared ASAR with ART score for the decision of
TACE repetition, and ASAR showed better performance
than ART score in the internal validation set (Supple-
mentary Table 2). In the external validation set, patients
with ASAR < 4 had also significantly longer OS than
Table 1 Baseline characteristics of the entire cohort (Continued)
Variables SNUH (n = 421) EUMC (n = 176) SMC (n = 739) P
AST (mg/dL) 42 (29–64) 44 (33–63.5) 49 (34–72) 0.089
ALT (mg/dL) 34 (22–54) 33 (23–53.5) 38 (24–58) 0.322
Total bilirubin (mg/dL) 0.8 (0.6–1.2) 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.487
Albumin (g/dl) 3.8 (3.4–4.1) 3.7 (3.4–4.0) 3.9 (3.5–4.2) 0.233
Alpha-fetoprotein (ng/mL)
≥200 89 (21.1) 49 (28.5) 194 (26.3) 0.084
< 200 332 (78.9) 123 (71.5) 545 (73.4)
NLR 1.85 (1.3–2.6) 1.90 (1.3–3.1) 1.6 (1.2–2.2) < 0.001
No. of TACE sessions 2 (1–2) 2 (1–4) 4 (2–7) < 0.001
Tumor response
CR + PR 332 (78.9%) 57 (32.4%) 616 (83.4) < 0.001
SD + PD 89 (21.1%) 119 (67.6%) 123 (16.6)
Abbreviations: SNUH Seoul National University Hospital, EUMC Ewha Womans University Medical Center, SMC Samsung Medical Center, HBV hepatitis B virus, HCV
hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, ALBI albumin-bilirubin grade, HAP score hepatoma arterial-embolization prognostic score, WBC white blood
cell, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, NLR neutrophil-lymphocyte ratio, TACE transarterial
chemoembolization, CR complete response, PR partial response, SD stable disease, PD progressive disease
aChronic hepatitis without cirrhosis was classified as Child-Pugh class A
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Table 2 Baseline characteristics of the derivation and internal validation subjects
Variables Total (n = 597) Derivation (n = 419) Internal validation (n = 178) P
Sex
Male 474 (79.4) 336 (80.2) 138 (77.5) 0.462
Female 123 (20.6) 83 (19.8) 40 (22.5)
Age (year) 63.9 ± 11.7 63.9 ± 11.8 64.1 ± 11.6 0.910
Etiology
HBV 386 (64.7) 329 (78.6) 113 (71.1) 0.868
HCV 82 (13.7) 62 (14.9) 26 (16.4)
alcohol 60 (10.1) 28 (6.5) 20 (12.5)
Cirrhosis
Yes 470 (78.7%) 336 (79.8%) 134 (76.1%) 0.317
Child-Pugh classa
A 479 (80.2) 340 (81.1) 139 (78.1) 0.391
B 118 (19.8) 79 (18.9) 39 (21.9)
BCLC stage
A 237 (39.7) 159 (37.9) 78 (43.8) 0.180
B 360 (60.3) 260 (62.1) 100 (56.2)
ALBI grade
1 204 (34.2) 146 (34.8) 58 (32.6) 0.046
2 363 (60.8) 258 (61.6) 105 (59.0)
3 30 (5.03) 15 (3.6) 15 (8.4)
HAP score
0 4 (0.7) 3 (0.7) 1 (0.6) 0.776
A 211 (35.3) 144 (34.4) 67 (37.6)
B 181 (30.3) 132 (31.5) 49 (27.5)
C 154 (25.8) 105 (25.1) 49 (27.5)
D 47 (7.9) 35 (8.4) 12 (6.7)
Modified HAP score
0 4 (0.7) 3 (0.7) 1 (0.6) 0.847
A 278 (46.6) 189 (45.1) 89 (50.0)
B 217 (36.3) 155 (37.0) 62 (34.8)
C 84 (14.1) 62 (14.8) 22 (12.4)
D 14 (2.3) 10 (2.4) 4 (2.2)
Tumor number
≤3 492 (82.6) 343 (82.1) 149 (83.7) 0.713
> 3 104 (17.4) 75 (17.9) 29 (16.3)
Tumor size (cm)
< 3 247 (41.4) 169 (40.3) 78 (43.8) 0.725
3–4 180 (30.1) 128 (30.5) 52 (29.2)
≥5 170 (28.5) 122 (29.1) 48 (27.0)
Hemoglobin (g/dL) 12.9 ± 2.1 13.0 ± 2.0 12.6 ± 2.2 0.08
WBC (×103/μL) 5.10 (3.9–6.3) 5.18 (3.9–6.4) 5.01 (3.8–6.1) 0.362
Platelet (×103/μL) 128 (83–170) 131 (84–176) 115.5 (79–160) 0.038
Prothrombin time (INR) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 0.133
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ASAR ≥4 (HR, 0.237; 95% CI, 0.189–0.298; P < 0.001;
Fig. 2c).
Sensitivity analyses
In the combined derivation and internal validation co-
horts (SNUH and EUMC), the low-risk group showed
significantly longer OS than that shown by the high-risk
group (HR, 0.249; 95% CI, 0.192–0.324; P < 0.001;
Fig. 3a). The median OS was 70.2 months in the low-risk
group vs. 17.7 months in the high-risk group. The 1-year
and 3-year survival rates were 92.1 and 69.7%, respect-
ively, in the low-risk group and 52.4 and 23.7%, respect-
ively, in the high-risk group. Among a subgroup of
patients with Child-Pugh class A, the low-risk group
showed significantly longer OS than the high-risk group
(HR, 0.260; 95% CI, 0.191–0.354; P < 0.001; Fig. 3b). The
1-year and 3-year survival rates were 93.4 and 72.4% in
the low-risk group, and 59.4 and 27.0% in the high-risk
group, respectively. Among the subgroup of patients
with Child-Pugh class B, the low-risk group showed sig-
nificantly longer OS than that shown by the high-risk
group (HR, 0.252; 95% CI, 0.151–0.420; P < 0.001;
Fig. 3c). The 1-year and 3-year survival rates were 85.2
and 53.4% in the low-risk group, and 46.3 and 6.6% in
the high-risk group, respectively.
Survivals from the subanalysis for BCLC-stage B pa-
tients were also comparable to those of the entire pa-
tients. The low-risk group showed significantly longer
OS than the high-risk group both in the derivation (HR,
0.293; 95% CI, 0.190–0.452; P < 0.001; Supplementary
Fig. 1a) and internal validation sets (HR, 0.261; 95% CI,
0.132–0.516; P < 0.001; Supplementary Fig. 1b). The 1-
year and 3-year survival rates of derivation set were 88.6
and 64.1% in the low-risk group, and 46.3 and 6.6% in
the high-risk group, respectively. The 1-year and 3-year
survival rates of validation set were 86.7 and 65.3%, in
the low-risk group, and 67.3 and 14.2% in the high-risk
group, respectively.
Survival prediction in child-Pugh class B patients before
the initial TACE
Because the initiation of first TACE is an important
issue for patients with Child-Pugh class B, we addition-
ally assessed the predictive performance for those pa-
tients using a modified version of the ASAR scoring
system, which comprised of only baseline components
(ALBI, size, and AFP) excluding initial TACE response,
i.e., “ASA(R)”. C-index values were 0.788 (95% CI,
0.702–0.876) in the derivation set, 0.745 (95% CI, 0.646–
0.862) in the internal validation set, and 0.670 (95% CI,
0.605–0.725) in the external validation set, respectively.
Using the cut-off score of 4 for this modified ASA(R) in
Child-Pugh class B patients, OS was also significantly
different among the derivation set (ASA(R) < 4 vs. ≥4:
HR, 0.317; 95% CI, 0.150–0.669; P < 0.001; Fig. 4a), the
internal validation set (ASA(R) < 4 vs. ≥4: HR, 0.225;
95% CI, 0.088–0.575; P < 0.001; Fig. 4b), and the external
validation set (ASA(R) < 4 vs. ≥4: HR, 0.261; 95% CI,
0.201–0.339; P < 0.001; Fig. 4c). ASA(R) showed signifi-
cantly better performance than other models for
Table 2 Baseline characteristics of the derivation and internal validation subjects (Continued)
Variables Total (n = 597) Derivation (n = 419) Internal validation (n = 178) P
Creatinine (mg/dL) 0.9 (0.7–1.0) 0.9 (0.8–1.0) 0.9 (0.7–1.0) 0.099
Sodium (mEq/L) 138.9 ± 3.1 139.0 ± 3.2 138.7 ± 3.0 0.377
AST (mg/dL) 42 (30–64) 42 (30–65) 42 (30–60) 0.627
ALT (mg/dL) 33 (22–54) 34 (23–55) 31 (21–54) 0.255
Total bilirubin (mg/dL) 0.8 (0.6–1.2) 0.8 (0.6–1.1) 0.8 (0.6–1.2) 0.383
Albumin (g/dl) 3.8 (3.4–4.1) 3.8 (3.4–4.0) 3.7(3.4–4.1) 0.158
Alpha-fetoprotein (ng/mL)
≥200 138 (23.3) 103 (24.8) 35 (19.8) 0.189
< 200 455 (76.7) 313 (75.2) 142 (80.2)
NLR 1.87 (1.3–2.7) 1.85 (1.3–2.6) 1.95 (1.3–2.8) 0.412
No. of TACE sessions 2.9 ± 2.8 3.0 ± 2.8 2.9 ± 2.9 0.290
Tumor response
CR + PR 389 (65.2%) 273 (65.2%) 116 (65.2%) 0.997
SD + PD 208 (34.8%) 146 (34.8%) 62 (34.8%)
Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, ALBI albumin-bilirubin grade, HAP score hepatoma arterial-
embolization prognostic score, WBC white blood cell, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, NLR
neutrophil-lymphocyte ratio, TACE transarterial chemoembolization, CR complete response, PR partial response, SD stable disease, PD progressive disease
aChronic hepatitis without cirrhosis was classified as Child-Pugh class A
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evaluating initial TACE suitability, such as HAP, modi-
fied HAP, and modified HAP II models in the internal
validation set (Supplementary Table 2).
Discussion
The prediction model (ASAR) of the present study
seems easily applicable for HCC patients undergoing
Table 3 Uni- and multivariate analysis for overall survival in the derivation cohort
Variables Univariate analysis Regression coefficient
(ß)
Multivariate analysis
HR (95% CI) P HR (95% CI) P
Sex
Female 0.940 (0.662–1.335) 0.731
Age (year) 1.024 (1.012–1.037) < 0.001
Etiology
Non-Viral ref
Viral 0.616 (0.437–0.870) 0.006
Child-Pugh class
A ref
B 1.591 (1.143–2.213) 0.006
ALBI grade
1 ref
2 2.231 (1.605–3.101) <.0001
3 6.602 (3.409–12.786) <.0001 0.832 2.299 (1.694–3.119) <.0001
HAP score
A-C ref
D 3.937 (2.872–5.399) <.0001
Modified HAP score
A-C ref
D 4.689 (3.012–7.300) <.0001
Tumor number
≤3 ref
> 3 1.615 (1.155–2.259) 0.005
Tumor size (cm)
< 3 ref
3–4 1.775 (1.231–2.560) 0.002
≥5 3.359 (2.368–4.763) <.0001 0.533 1.704 (1.424–2.038) <.0001
Hemoglobin (g/dL) 0.851 (0.796–0.909) <.0001
Log WBC 1.452 (0.988–2.132) 0.058
Log platelet 1.165 (0.875–1.551) 0.296
Log prothrombin time (INR) 9.847 (3.454–28.076) <.0001
Log creatinine 1.907 (1.377–2.640) <.0001
Sodium 0.937 (0.898–0.977) 0.002
Log AST 2.332 (1.833–2.966) <.0001
Log ALT 1.231 (1.010–1.499) 0.039
Log Total bilirubin 1.191 (0.900–1.574) 0.221
Alpha-fetoprotein
< 200 ref
≥200 1.774 (1.313–2.397) <.0001 0.460 1.583 (1.164–2.154) 0.0034
NLR 1.91 (1.444–2.525) <.0001
Tumor response
CR + PR ref
SD + PD 2.292 (1.733–3.032) <.0001 0.650 1.915 (1.431–2.563) <.0001
Abbreviations: HR hazards ratio, ref. reference, ALBI albumin-bilirubin grade, HAP score hepatoma arterial-embolization prognostic score, INR international normalized ratio, AST
aspartate aminotransferase, ALT alanine aminotransferase, NLR neutrophil-lymphocyte ratio, CR complete response, PR partial response, SD stable disease, PD
progressive disease
Nam et al. BMC Cancer          (2020) 20:504 Page 9 of 14
TACE in practice and may be helpful in decision making
on TACE repetition. This prediction model incorporated
objective assessment of baseline hepatic functional re-
serve as well as tumor burden and treatment response,
achieving better predictive performance compared to
other prediction models. In addition, the modification of
this model using only baseline factors also showed
meaningful predictive value in patients with Child-Pugh
class B, which could particularly be helpful for the deci-
sion on the initiation of TACE.
Although TACE is the standard-of-care for patients with
intermediate-stage HCC (BCLC stage B), these patients
encompass a wide range of the disease spectrum [25].
Thus, several prediction models have been developed to
select more suitable patients for TACE, such as ART
score, ABCR (AFP, BCLC, Child-Pugh score, and re-
sponse) score, (modified) HAP score, and STATE-score
[7, 9, 25, 26]. However, it seems premature to widely apply
these models in practice given that they have not shown
consistent results in subsequent studies [11, 27].
When designing the present study, we raised two prac-
tical questions regarding the decision for TACE. The
first one was “when to stop TACE?” in patients with
good hepatic function who proceed to first TACE with
less concerns on the potential deterioration of hepatic
function (i.e., mostly Child-Pugh class A). For those pa-
tients, early prediction of TACE failure or refractoriness
seems more relevant, in order to switch to systemic ther-
apy before their hepatic functions deteriorate with futile
repetition of TACE [21, 28]. The other question was
“whether to proceed to first TACE or not” in patients
with impaired hepatic functional reserve at the time of
HCC diagnosis. Although its use is not generally encour-
aged for these patients, TACE sometimes becomes the
only treatment option, particularly when tumor burden
exceeds the criteria for liver transplantation or when
transplantation is not readily feasible due to organ short-
age. Systemic therapy also has not been proved to be ef-
fective in these patients [2, 3, 29]. Hence, cautious
application of TACE for properly selected patients with
Child-Pugh score ≤ B8 might be beneficial for these
patients, given that Child-Pugh score > 8 is generally
regarded as a contraindication for TACE [30].
The prediction model of this study includes four rele-
vant risk factors, namely, ALBI grade, maximal tumor
size, baseline AFP, and initial TACE response. For hep-
atic functional assessment, especially in HCC patients,
ALBI grade has proved to be useful in previous studies
[14] as well as in our cohorts. The conventional Child-
Pugh scoring system has been used widely as a standard
method for the assessment of hepatic function in HCC
patients until now. However, the Child-Pugh system in-
cludes subjective (due to grade of ascites and hepatic en-
cephalopathy) and interrelated (i.e., albumin and ascites)
components, and has no weighting scores on each com-
ponent [13]. The recently developed ALBI grade offers a
simple, objective, and discriminatory method of asses-
sing hepatic function in patients with HCC [16]. Because
the Child-Pugh system is still used as a primary measure
for the selection of treatment options in major HCC
guidelines [2, 3], we adopted a step-wise approach in this
study. First, because TACE is recommended for Child-
Pugh class A and highly selected class B, such patients
were first selected (i.e., ‘entire cohort’) and the predic-
tion model was developed. Then, the predictive perform-
ance of the model was evaluated in Child-Pugh class A
and B patients separately. While our model originally ex-
presses an adaptive strategy using baseline characteris-
tics plus initial TACE response to provide information
on when to stop TACE, the modified model which only
includes the baseline factors, i.e., “ASA(R)”, well discrim-
inated the prognostic subgroups for Child-Pugh class B
patients, suggesting the usefulness in selecting patient
suitability for first TACE in patients with impaired hep-
atic function.
Tumor size and AFP level reflect tumor burden in our
model, and were also included in previous prediction
models such as ABCR and HAP score [8, 31]. Although
tumor number was also a relevant prognostic factor in the
multivariable analysis, it was excluded in our final predic-
tion model from the stepwise selection procedure for the
model derivation. Some previous models also excluded
tumor number, for example, models for the decision of first
TACE (HAP, modified HAP) and ART score (for TACE
repetition) [7–9]. However, other models included
tumor number, such as the STATE score, modified
HAP-II score, and “six-and-twelve” score (all for the
decision of first TACE) or SNACOR (for TACE
repetition) [26, 32–34]. Tumor size is a well-known
factor for determining the achievement of objective
response following TACE [35]. Moreover, because
the majority of the study population in the entire
cohort had 3 or less tumors, the relative relevance of
tumor number might have been offset in the deriv-
ation of the model.
Table 4 ASAR (ALBI-size-AFP-response) scoring system
Score
0 1 2
ALBI grade 1 2 3
Maximal tumor diameter (cm) < 3 3–5 ≥5
AFP (ng/mL) < 200 ≥200
Tumor response CR, PR SD, PD
Abbreviations: ALBI albumin-bilirubin grade, AFP alpha-fetoprotein, CR
complete response, PR partial response, SD stable disease, PD
progressive disease
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TACE response has been included in previous models
for decision making on TACE repetition [7, 31, 32] as
well as in consensus papers or guidelines defining TACE
refractoriness [28, 36–38]. TACE failure or refractori-
ness in the literature mostly requires two consecutive
absences of objective response, which is not supported
by solid evidences. In the present study, we assessed the
relevance of initial TACE response and incorporated it
as a component of the model, given that an initial TACE
response was the most robust predictor for the outcome
in a recent study [39]. Furthermore, recent advances in
systemic treatment options for HCC, such as second-
line agents or immunotherapy, appear to facilitate earlier
decision on whether to repeat TACE or switch to sys-
temic therapy [40, 41]. The concept of treatment stage
migration or switching to a systemic agent such as soraf-
enib might be of little benefit once hepatic functional
deterioration develops with repeated TACE [29]. Given
that earlier prediction of TACE failure was the funda-
mental goal of the present study, on-treatment hepatic
functional deterioration, such as increase in the Child-
Pugh score, was not taken into consideration for model
derivation, because further treatment would quite be
limited with Child-Pugh score increase under repeated
TACE. Instead, our model was developed to predict
TACE failure earlier using the initial TACE response in
Fig. 2 (a-c) Survival analyses of the derivation and validation set according to ASAR score. ASAR scores (cut-off = 4) offered similar predictive
performance of overall survival in the internal and external validation set compared to that in the derivation set
Fig. 3 (a-c) Survival analyses of subgroups according to Child-Pugh class with ASAR score in the entire cohort. When applying ASAR score (cut-
off = 4), overall survivals were significantly different in all enrolled patients as well as in patients with Child-Pugh class A or B
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Child-Pugh class A patients, thereby enabling an earlier
switch to systemic treatment, and to prevent harmful re-
sults of TACE initiation in Child-Pugh class B patients
using solely baseline characteristics as described earlier.
The strengths of the prediction model in the present
study comprise its simplicity and good performance,
which was derived from a relatively large study popula-
tion from institutions with plenty of experience in TACE
and technical similarity in the TACE procedure. More-
over, the performance of this model showed reproduci-
bility in both internal and external validations. However,
there are several limitations in the present study. First,
tumor number may be a relevant component for the
prediction model as shown in previous studies, although
it was not included in the stepwise selection for model
derivation in the present study. In addition, relevance of
tumor markers other than AFP, particularly protein in-
duced by vitamin K antagonist-II, was not evaluable be-
cause of incomplete data. These potentially relevant
tumor-related factors need to be evaluated for the pre-
diction model. Lastly, although this was a multi-
institutional study including a relatively large number of
patients, model derivation and validation were con-
ducted in a combined set of two institutional cohorts
(SNUH, EUMC) instead of using each institutional co-
hort as either derivation or validation set, because sev-
eral baseline characteristics were significantly different
between the two cohorts. At least, however, our model
was equally discriminatory when applied to each institu-
tional cohort separately and we also validated the model
externally in an independent cohort.
Conclusion
In conclusion, a simple scoring system (ASAR) may be
helpful for decision making on the repetition and/or ini-
tiation of TACE in patient with unresectable HCC. This
prediction model could be applied differently according
to patients’ baseline hepatic functional reserve, that is,
an earlier switch or treatment stage migration based on
the score with the initial TACE response for patients
with good baseline hepatic function versus decision on
whether to implement first TACE or not for patients
with impaired hepatic function based on baseline factors
only. The former strategy could lead patients to systemic
therapy prior to further deterioration of hepatic func-
tion, and the latter could help patients avoid potentially
harmful treatment.
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Additional file 1 Supplementary Fig. 1 (a, b) Survival analyses of
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mHAP in validation set. Between high and low risk group according to
HAP and modified HAP score, overall survivals were not significantly
different.
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the SNUH and EUMC cohort Supplementary Table 2. Comparison of c-
indices among models in internal validation cohort Supplementary
material.
Fig. 4 (a-c) Overall survival in patients with Child-Pugh class B according to the modified model without initial TACE response (ALBI, size of
tumor, and AFP) in the derivation and validation sets. When applying the modified model (cut-off = 4) score only in patients with Child-Pugh
class B, overall survivals were significantly different in patients in the derivation and the internal and external validation sets
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